Literature DB >> 33939382

Lymph Node Tumor Burden Correlates With Tumor Budding and Poorly Differentiated Clusters: A New Prognostic Factor in Colorectal Carcinoma?

Ivan Archilla1, Sherley Díaz-Mercedes, José Javier Aguirre, Jordi Tarragona, Isidro Machado, Maria Teresa Rodrigo, Sandra Lopez-Prades, Iñigo Gorostiaga, Stefania Landolfi, Begoña Otero Alén, Francesc Balaguer, Antoni Castells, Jordi Camps, Miriam Cuatrecasas.   

Abstract

INTRODUCTION: Molecular lymph node (LN) staging in early colorectal cancer (CRC) has demonstrated to be more precise than conventional histopathology pN staging. Tumor budding (TB) and poorly differentiated clusters (PDCs) are associated with LN metastases, recurrences, and lower survival in CRC. We evaluated the correlation between the total tumor load (TTL) in LNs from CRC surgical specimens with patient outcome, TB, and PDC.
METHODS: In this retrospective multicentre study, 5,931 LNs from 342 stage I-III CRC were analyzed by both hematoxylin and eosin and molecular detection of tumor cytokeratin 19 mRNA by one-step nucleic acid amplification. TB and PDC were evaluated by hematoxylin and eosin and cytokeratin 19 immunohistochemistry.
RESULTS: One-step nucleic acid was positive in 38.3% patients (n = 131). Tumor Budding was low in 45% cases, intermediate in 25%, and high in 30%. Poorly Differentiated Clusters were low-grade G1 in 53%, G2 in 32%, and G3 in 15%. TB and PDC correlated with TTL, high-grade, lymphovascular and perineural invasion, pT, pN and stage (P < 0.001). TB, PDC, and TTL ≥ 6,000 copies/µL were associated with worse overall survival (P = 0.002, P = 0.013, and P = 0.046) and disease-free survival (P < 0.001). DISCUSSION: The implementation of more sensitive molecular methods to assess LN status is a promising alternative approach to pN staging, which could be integrated to other factors to help risk stratification and management of patients with early-stage CRC. This study demonstrates the correlation of the amount of LN tumor burden with TB and PDCs. TTL is related to the outcome and could be used as a new prognostic factor in CRC (see Visual Abstract, Supplementary Digital Content 2, http://links.lww.com/CTG/A512).

Entities:  

Year:  2021        PMID: 33939382     DOI: 10.14309/ctg.0000000000000303

Source DB:  PubMed          Journal:  Clin Transl Gastroenterol        ISSN: 2155-384X            Impact factor:   4.488


  2 in total

1.  Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.

Authors:  Enrique Trilla; Juan Morote; Mercè Cuadras; Jacques Planas; Ana Celma; Lucas Regis; Inés M de Torres; M Eugenia Semidey
Journal:  BMC Cancer       Date:  2022-04-02       Impact factor: 4.430

Review 2.  Role of one-step nucleic acid amplification in colorectal cancer lymph node metastases detection.

Authors:  Francesco Crafa; Serafino Vanella; Onofrio A Catalano; Kelsey L Pomykala; Mario Baiamonte
Journal:  World J Gastroenterol       Date:  2022-08-14       Impact factor: 5.374

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.